Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/104407
Title: Type 2 diabetes, antidiabetic medications, and colorectal cancer risk: two case-control studies from Italy and Spain
Author: Rosato, Valentina
Tavani, Alessandra
Gracia-Lavedan, Esther
Guinó, Elisabet
Castaño-Vinyals, Gemma
Villanueva, Cristina M.
Kogevinas, Manolis
Polesel, Jerri
Serraino, Diego
Pisa, Federica E.
Barbone, Fabio
Moreno Aguado, Víctor
La Vecchia, Carlo
Bosetti, Cristina
Keywords: Antidiabètics
Diabetis
Càncer colorectal
Insulina
Metformina
Factors de risc en les malalties
Itàlia
Espanya
Hypoglucemic agents
Diabetes
Colorectal cancer
Insulin
Metformin
Risk factors in diseases
Italy
Spain
Issue Date: 6-Oct-2016
Publisher: Frontiers Media
Abstract: Background: type 2 diabetes mellitus has been associated with an excess risk of colorectal cancer, although the time-risk relationship is unclear, and there is limited information on the role of antidiabetic medications. Aim: we examined the association between type 2 diabetes, antidiabetic medications, and the risk of colorectal cancer, considering also duration of exposures. Methods: we analyzed data derived from two companion case-control studies conducted in Italy and Spain between 2007 and 2013 on 1,147 histologically confirmed colorectal cancer cases and 1,594 corresponding controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional multiple logistic regression models, adjusted for socioeconomic factors and major potential confounding factors. Results: overall, 14% of cases and 12% of controls reported a diagnosis of diabetes, corresponding to an OR of colorectal cancer of 1.21 (95% CI 0.95-1.55). The OR was 1.49 (95% CI 0.97-2.29) for a duration of diabetes of at least 15 years. The OR was 1.53 (95% CI 1.06-2.19) for proximal colon cancer, 0.94 (95% CI 0.66-1.36) for distal colon cancer, and 1.32 (95% CI 0.94-1.87) for rectal cancer. In comparison with no use, metformin use was associated with a decreased colorectal cancer risk (OR 0.47, 95% CI 0.24-0.92), while insulin use was associated with an increased risk (OR 2.20, 95% CI 1.12-4.33); these associations were stronger for longer use (OR 0.36 and 8.18 for ≥10 years of use of metformin and insulin, respectively). Conclusion: this study shows evidence of a positive association between diabetes and colorectal cancer, mainly proximal colon cancer. Moreover, it indicates a negative association between colorectal cancer and metformin use and a positive association for insulin use.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fonc.2016.00210
It is part of: Frontiers in Oncology, 2016, vol. 6, p. 210
Related resource: https://doi.org/10.3389/fonc.2016.00210
URI: http://hdl.handle.net/2445/104407
ISSN: 2234-943X
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
665147.pdf131.47 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons